Brexit uncertainty favours internationally focused pharmaceutical professionals
Its likely that a number of firms will relocate their services to mainland Europe or Ireland.
The uncertainty over the state of the pharmaceutical industry following Brexit will favour internationally focused professionals, according to NonStop Recruitment.
With the UK deciding to leave the EU last month, a number of commentators have suggested that the sector will face ‘immediate challenges’ including the regulation of medicine, funding research and the potential relocation of The European Medicines Agency. NonStop has warned that professionals with internationally focused skill sets, such as foreign languages and wider commercial experience, are likely to be the ones to benefit from this new landscape.
Matt Beedle, Team Leader within NonStop Pharma, comments: “While we obviously can’t be certain about the future of the market, it seems highly likely that a number of firms will relocate their services to mainland Europe or Ireland, probably to match the relocation of The European Medicines Agency, which is the reason many companies base their operations in London in the first place. This means that these firms will have to move their staff and not everyone is well suited to a role working on foreign shores, for a variety of reasons. Consequently, from our analysis we believe that professionals with an internationally focused skill set are likely to have the best prospects in this new climate.”
“The full extent of the UK’s decision to leave the single market will remain to be seen, but it’s also likely that we’ll face added challenges with both funding cuts and firms no longer having access to EU grants. However, these are longer term issues and in the short term it’s likely that pharmaceutical professionals will be concerned over their job security. The market is so tumultuous at the moment that it’s hard to make an accurate prediction for the future, but we believe that those individuals who can highlight their internationally focused attributes and experience will prosper.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance